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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.002Forward genetic analysis is an unbiased approach for identifying genes essential to deﬁned biological
phenomena. When applied to mice, it is one of the most powerful methods to facilitate understanding
of the genetic basis of human biology and disease. The speed at which disease-causing mutations can
be identiﬁed in mutagenized mice has been markedly increased by recent advances in DNA sequencing
technology. Creating and analyzing mutant phenotypes may therefore become rate-limiting in forward
genetic experimentation. We review the forward genetic approach and its future in the context of recent
technological advances, in particular massively parallel DNA sequencing, induced pluripotent stem cells,
and haploid embryonic stem cells. (Am J Pathol 2013, 182: 1462e1473; http://dx.doi.org/10.1016/
j.ajpath.2013.02.002)Supported by NIH grants HHSN272200700038C and AI100627-01 (B.B.).Beginning with the mechanistic assertion that living organ-
isms are biological machines, it is incumbent on biologists to
understand the workings of these machines. Acquiring a list
of parts (proteins) with determinative importance in any
particular biological function is often the ﬁrst step in such
understanding. Genetics can provide that list, and it is left to
other disciplines (biochemistry, cell biology, and structural
biology) to determine how the parts are shaped, where they
reside within cells, and how they ﬁt together.
Genetic studies in a physiological setting generally require
a model organism that can be experimentally manipulated in
a controlled environment. The laboratory mouse serves as the
premier model system for study of mammalian biology on
a molecular level. Ninety-nine percent of human genes have
homologues in mice (ie, 99% of human and mouse genes
have a shared ancestry), and 80% have orthologs (ie, 80% of
human and mouse genes with shared ancestry have remained
intact and unduplicated since their last common ancestor); in
addition, 90% of the mouse genome exists in segments in
which the gene order has been conserved with that in the
human genome.1,2 Thus, discoveries made using mice
usually have corresponding implications in humans. Impor-
tantly, mouse geneticists have acquired many robust tools
with which to probe the mouse genome. Mice have been
inbred to produce hundreds of strains that are homozygous atstigative Pathology.
.all loci. Most mouse genes have been inactivated (at least in
embryonic stem cells, with a smaller fraction also in mice) by
gene targeting or gene trapping,3,4 and almost all genes will
eventually be inactivated by these and other methods, notably
chemical mutagenesis.5 A ﬁnished genome sequence has
been established and annotated for one strain (C57BL/6J),1,2
and the genomes of other inbred strains have been sequenced
and annotated in part.6e8 Finally, techniques for the manip-
ulation of the mouse genome and/or mouse embryos to create
chimeric, transgenic, knockout, knockin, or conditionally
mutant mice with targeted gain- or loss-of-function mutations
are well established and commonly available.9e11 More
recently, induced pluripotent stem cells (iPSCs) and haploid
embryonic stem cells (ESCs) have been described12e14; the
utility of these new cell types to genetic research is likely to
be great.
Since genetics was established as a science >100 years
ago, geneticists have begun their work by ﬁnding exceptions
to normal function (phenotypes). In recent decades, mouse
geneticists have been able to identify the genetic changes
responsible for individual phenotypes. At one time, this was
a daunting task. However, the process has accelerated
sharply during the past few years, empowered by advances
Advances in Mouse Forward Geneticsin chemistry, engineering, and computational biology. In
some cases, the molecular cause of a newly observed
phenotype can now be established within days or weeks.
The most important recent technological advance in mouse
genetics has been the development of massively parallel
DNA sequencing, which enables rapid and cost-effective
interrogation of whole genomes or exomes. In this review,
we discuss the forward genetic approach as applied to mice,
discoveries it has delivered, and the future of forward
genetics in the context of recent technological advances.
The Forward Genetic Approach
Reverse genetics begins with a known gene and experi-
mentally investigates the effects of altering the sequence or
expression of that gene.15 The reverse genetic approach
can yield deep understanding of the function of individual
genes but is limited by hypotheses about the phenotypic
outcome of the targeted genetic alteration.16 In contrast, the
forward genetic approach begins with a particular biological
phenomenon or characteristic and asks, “Which genes are
necessary to support this phenomenon?”17,18 Mice that
show a variant phenotype are found or created using a
random process, and the mutational cause is determined by
mapping and then positional cloning. Genes implicated in
this way can reveal the biological basis of the phenomenon.
Gradations of phenotype that result from mutations in
different genes may suggest which genes are essential and
which have more peripheral roles in a given process. By far
the most important advantage of the forward genetic
approach is the unbiased nature of inquiry, which requires
no hypotheses regarding the molecular basis of the pheno-
type in question. Because of this, forward genetics has led to
many new and unexpected discoveries. In the ﬁeld of
immunology, Toll-like receptor (TLR)-4 was identiﬁed as
the sensor of lipopolysaccharide by this approach.19 So too
was Foxp3 revealed as a transcription factor essential for the
development of regulatory T cells.20,21
A steady supply of phenotypic variation (phenovariance) is
necessary for laboratories intending to perform forward
genetic studies, and two main sources meet this need. Spon-
taneous mutations resulting in naturally occurring phenovar-
iance among divergent mouse strains provide abundant
material for study.6 Because distantly related mouse strains are
distinguished by millions of nucleotide differences, they are
particularly suited to the study of complex traits. Complex
traits are those in which genetic differences at multiple loci
produce a deﬁned phenotype. Natural variation in quantitative
traits is also commonly found among divergent strains of
mice,22 which may serve as a useful model of quantitative
traits in humans. However, because of the numerous differ-
ences between mouse strains [even within a small (approxi-
mately 100-kbp) genomic interval], causative mutations are
more difﬁcult to pinpoint accurately, which means that correct
identiﬁcation requires more reﬁned mapping of phenotypes at
greater expense in terms of time and resources. To overcomeThe American Journal of Pathology - ajp.amjpathol.orgthis challenge, the Collaborative Cross aims to capture the rich
natural variation present in eight diverse inbred strains of mice
by intercrossing and then inbreeding them to create >600
individual inbred strains that will be systematically genotyped
and phenotyped.23
Spontaneous mutations within a strain also cause phe-
novariance between individuals; agouti (A)24 and obese
(ob)25 were such mutations and were identiﬁed by mapping
and positional cloning. Spontaneous mutations, however,
arise at a rate insufﬁcient for most forward genetic labora-
tories and cannot be relied on as a source of phenovariance.
Alternatively, random mutagenesis of the germline can be
performed to create mutations in mice of uniform strain
background and mutant offspring carrying heterozygous or
homozygous mutations systematically screened for pheno-
types of interest. Random mutagenesis and phenotypic
screening have been applied extensively and with great
success to Saccharomyces cerevisiae, Caenorhabditis ele-
gans, Drosophila melanogaster, and Arabidopsis thaliana,
validating the utility of this method. The method is equally
applicable to mice, albeit more difﬁcult because of the greater
expense of their care, and the relatively large size of the mouse
genome. Indeed, we and others have successfully used this
strategy in mice to uncover genes with previously unknown
and essential functions in antibody responses to immunization
(Zeb1, Ruvbl2, Nfkbid ),26 B lymphopoiesis (Atp11c),27,28
T-cell signaling (Card11),29 TLR signaling (Cd36, Unc93b1,
Ticam1),30e32 systemic autoimmunity (Rc3h1),33 and intes-
tinal homeostasis (Yipf6),34 discoveries that might not have
been made using a hypothesis-driven approach.
The phenomenon chosen for study should be important in
the eyes of the investigator, and the phenotypic screen must
be robust. A screen that produces many false-positive results
will sap resources, whereas a screen that is insensitive will
miss many of the key genes responsible for the phenomenon
in question. If narrow in scope, a screen may yield few hits,
but it is possible that these hits will be readily comprehen-
sible. If broad in scope, many hits may result, but mecha-
nistic interpretation may be difﬁcult. Functional redundancy
limits the power of forward genetics and at times can only
be assessed by trial and error. One guide to feasibility is the
presence of interstrain or interspecies phenovariance. If it
exists, it is at least possible that single mutations may also
cause phenovariance.
ENU Mutagenesis
Phenotypic variation can be generated using germline
mutagenesis, induced with chemicals,35,36 radiation,37,38 or
transposons.39 The chemical N-ethyl-N-nitrosourea (ENU)
is a powerful mutagen for mouse spermatogonial cells40 and
is currently the compound most widely used for mutagen-
esis of mice. The mutagenic action of ENU involves the
transfer of the ethyl group of ENU to a nucleophilic nitrogen
or oxygen in DNA.41,42 The resulting adducts cause mis-
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Figure 1 Inbreeding protocol for generating G3 mice with homozygous
ENU-induced mutations. Mutagenized G0 males are bred to G00 females,
which carry germline mutations derived from other mutagenized males. G1
mice are either intercrossed as shown here or crossed to wild-type C57BL/
6J females. Siblings in the G2 generation are intercrossed. G3 mice are
subjected to screening. Small asterisks represent mutations derived from
the G0 male (red) and G00 female (blue); large asterisks indicate initial
germline transmission of the mutation.
Moresco et alENU-induced mutations are single-bp substitutions that
cause missense errors, splice site errors, and nonsense
mutations, in order of declining frequency.43e45 Interest-
ingly, some mutations induced by ENU display asymmetry
in their frequency of occurrence within the sense versus
antisense strand.43,46 Substitutions involving T/A pairs (A/T
to T/A and A/T to G/C) are the most common ENU-induced
changes, but T to A occurs more frequently in the sense
strand than in the antisense strand. A similar strand asym-
metry is observed for T to C transitions. Neither instance of
asymmetry can be explained by the frequency of the target
nucleotide within sense versus antisense strand.
When administered to male C57BL/6J mice at the most
common dosage (three weekly i.p. injections at 90 mg/kg),
ENU creates an average of 60 coding changes per sperm,5
which would correspond to approximately one mutation
per 700,000 bp of target DNA sequence (slightly more than
previous estimates of one mutation per 1 to 2.7 Mbp of
genomic sequence for the frequency of ENU-induced
mutations).46e48 Given the types and frequency of ENU-
induced mutations, observed phenotypes are almost
always of monogenic origin. Moreover, when a phenotype
is observed, it almost always results from structural changes
in proteins rather than from effects on cis-acting regulatory
elements that govern the amount or location of protein
synthesis.43,49 Other mutagens, such as X-rays38 or chlor-
ambucil,50,51 typically induce large-scale genomic alter-
ations, including translocations, inversions, and deletions,
and may be better suited for analysis of regulatory regions.
Methods for mutagenizing male mice and inbreeding
them to recover homozygous mutations have been described
previously.52e54 In our laboratory, we use a breeding
scheme in which a mutagenized C57BL/6J male (G0) is
crossed to a G00 female derived from an independent ENU-
mutagenized male (Figure 1). G1 mice are either crossed to
C57BL/6J females or intercrossed to yield G2 mice, and G3
mice carrying homozygous mutations are derived from G2
intercrosses.54 Based on a mutation rate of 1.4 per Mbp of
DNA, an estimated 90 mutations are expected to result in
nonsynonymous coding change in each G1 mouse generated
using this breeding scheme. On average, each G3 mouse
contains a total of 45 mutations, of which about six are
homozygous and approximately 39 are heterozygous.
Mutation Mapping as It Once Was
Although simple in principle, the process of mapping and
identifying a mutation responsible for a given phenotype was
for many years the greatest challenge of forward genetics. The
process began with genetic mapping, which entailed out-
crossing affectedmice to a different inbred strain (the mapping
strain) and backcrossing or intercrossing the F1 hybrid
progeny. When a recessive mutation was at issue, F2 mice
were tested for phenotype and then genotyped individually at
markers distributed across the genome, distinguishing the
mutant and mapping strains. Concordance between the mutant1464phenotype and homozygosity for one or more markers of the
mutant strain suggested linkage of a particular chromosomal
region with the mutant phenotype. The genotyping of addi-
tional markers within the region of linkage made it possible to
localize the mutation to a smaller chromosomal region. This
process of ﬁne mapping deﬁned a proximal and a distal
marker, each separated from the mutation by one or more
crossover events, and thus delimited the proximal and distal
boundaries of the critical region. Thus, a reﬁned critical region,
perhaps 1 to 3 Mb in length could be established, and all
coding exons within it would be PCR ampliﬁed and sequenced
directly. On average, 1 Mb of genomic DNA contains 8.7
genes, and each gene contains 8.8 exons. However, because
genes are not uniformly distributed but instead are clustered
within the genome, many more genes (and coding exons)
might reside within a 1-Mb critical region. The entire mapping
process, but especially ﬁne mapping, required extensive
breeding. Sometimes thousands of meioses were used to
narrow a gene-rich critical region to<1 Mb. In some cases, if
a gene happened to reside within a region of the genome that
was resistant to meiotic recombination, the critical region
might remain much larger: 5 Mb or longer.
Before the publication of an annotated mouse genome
sequence, the content of the genome, with respect to both
genes and markers, remained largely mysterious. Accord-
ingly, a physical mapping step was applied, in which all DNA
within a critical region was cloned into bacterial artiﬁcial
chromosomes or yeast artiﬁcial chromosomes, which were
then surveyed for genes and polymorphic markers (usually
simple sequence repeats). Several methods were used toajp.amjpathol.org - The American Journal of Pathology
Advances in Mouse Forward Geneticsidentify genes within unannotated DNA sequences. Exon
trapping was performed by cloning fragments of genomic
DNA into vectors that would be expressed in mammalian
cells, given the presence of functional splice junctions.
cDNA cloning was used to retrieve and identify the expressed
fragments, which were then sequenced, and designated as
putative exons. Hybridization selection was a second tech-
nique, in which cDNA was allowed to hybridize with
immobilized genomic DNA and then eluted, cloned, and
sequenced to pinpoint expressed genes within the genome.
Computational algorithms such as GRAIL were also used to
predict the existence of genes within unannotated stretches of
genomic DNA, assembled from shotgun sequencing of
bacterial artiﬁcial chromosomes.
Expressed sequence tags, derived from the random
sequencing of millions of cDNA molecules from many
different tissues, were a breakthrough55 that permitted much
more rapid and reliable identiﬁcation of genes. Genomic
DNAcould be sequenced and then analyzed byBLAST (basic
local alignment search tool) against an expressed sequence tag
database to determine whether it contained elements with
strong homology to expressed sequences. However, because
expressed sequence tag libraries were not comprehensive, it
was necessary to perform BLAST analyses recurrently (often
at monthly intervals) to be sure that one did not overlook
newly discoverable genes. Moreover, homologs and exact
matches needed to be treated as candidate genes, notwith-
standing the fact that most of them were eventually discarded
as pseudogenes. Finally, for every authentic gene within the
critical region, thorough sequencing was performed using
both wild-type and mutant genomic DNA as templates to
identify the causative mutation.
DNA sequencing to ﬁnd and then examine genes in the
critical region were often the rate-limiting steps in positional
cloning. Before the introduction of massively parallel
sequencing technology, DNA sequencers used the Sanger
sequencing method that relied on DNA chain termination on
incorporation of dideoxynucleotide analogs. Initially, radio-
nuclide detection was used, necessitating manual reading of
sequencing ladders on photographic ﬁlm. Later ﬂuorescence
detection supplanted radionuclide detection,56 but manual
tracking of sequences generated within slab gels was
required, and a few tens of thousands of bases could be read
per day, even with several sequencing machines. Capillaries
supplanted slab gels as a separation medium,57 leading to
greater automation, and as many as 1 million bp of sequence
could be captured per machine per day as these machines
reached their highest level of sophistication.
Altogether, identifying amutationmight occupy a large and
competent laboratory for 5 to 8 years. The availability of
a trusted reference sequence of the mouse genome usually
eliminated the need to perform physical mapping and the need
to identify candidate genes within a critical region. However,
the time and resources needed to map a mutation to a chro-
mosomal interval small enough for sequencing remained
substantial. In early postgenomic times, identifying amutationThe American Journal of Pathology - ajp.amjpathol.orgmight typically take an entire year (although several mutations
might be pursued simultaneously) (Figure 2).
Seeking to automate the process of exploring critical
regions,54 we wrote software to design primers ﬂanking the
coding region to be ampliﬁed within any part of the genome. A
robotwas then programmed tomixprimers andDNA templates
(from mutant and wild-type mice) for PCR ampliﬁcation.
Puriﬁcation and mixing of PCR products with sequencing
primers and reagents were also performed robotically in 96- or
384-well plate format. Sequencingof96 samples could proceed
inparallel, yielding50 to 60kbpof sequence per plate andabout
half a million bp of sequence per day. The resulting sequence
trace ﬁles were analyzed with Phred version 0.020425.c
(University of Washington, Seattle, WA) and Phrap version
0.990319 (University of Washington),58e60 programs that call
bases from sequence chromatograms and compare and align
multiple reads with a reference sequence, also giving each peak
a score reﬂecting the quality of the read. Software was used to
identify discrepancies betweenmutant andwild-type sequences
or, if sequencing failed, to redesign new primers for a repeat of
the process. Although these tools substantially accelerated the
mutation identiﬁcation process, massively parallel sequencing
soon surpassed them in efﬁciency and utility.
Massively Parallel Sequencing
Among the ﬁrst published massively parallel sequencing
technologies was massively parallel signature sequencing in
an article appearing in 2000,61 although conceptual devel-
opment of early methodologies to support large-scale
DNA sequencing was underway beginning in the early
1990s.62e65 The ﬁrst massively parallel sequencing instru-
ment introduced to the commercial market was the GS-20
produced by 454 Life Sciences (now 454 Life Sciences,
a Roche company, Brandford, CT) in 2005, which was
followed shortly thereafter by the Solexa (now Illumina,
Inc., San Diego, CA) Genome Analyzer in 2006 and the
Applied Biosystems (now Life Technologies, Carlsbad, CA)
SOLiD sequencer in 2007. These machines were capable of
producing hundreds of megabase pairs of sequence per day,
compared with hundreds of kb pairs of sequence per day in
capillary (Sanger reactionebased) sequencers. Cost per bp
of sequence was reduced to a fraction of the cost per bp in
capillary sequencers, whereas sequencing accuracy was re-
ported to be upward of 98.5% per bp and much enhanced by
deep coverage of a speciﬁc target region.66
Massively parallel refers to the simultaneous sequencing
of large numbers (millions to billions) of DNA fragments,
and the new instruments accomplish this using chemistry
distinct from the Sanger reaction. The older capillary
sequencers worked by separating Sanger reaction mixtures
by electrophoresis in capillary tubes and then detecting the
ladder of ﬂuorescent reaction products by their speciﬁc
wavelength of emitted light. Massively parallel sequencers
begin with a population of DNA fragments (a library),
which are attached to a solid support, such as a glass bead or1465
Figure 2 Workﬂow typical in 2005, 2008, and currently for identifying a mutation responsible for a variant phenotype. Estimated time requirements are
indicated for eachmajor step. Left panel: Around 2005, identifying amutation causative for a particular phenotype by geneticmapping and capillary sequencing of
critical region coding sequences commonly required approximately 1 year. Center panel: More efﬁcient mapping by bulk segregation analysis (BSA) and massively
parallel genome sequencing were implemented for mutation ﬁnding beginning around 2008 and reduced by approximately 55% the time needed to ﬁnd a causative
mutation (counting the time from conﬁrmation of transmissibility). Right panel: Identiﬁcation of causative mutations without genetic mapping has recently been
demonstrated, made possible by the high accuracy of massively parallel sequencers and the use of multiple data ﬁlters to exclude false-positive mutation calls. This
process results in the identiﬁcation of only a few mutations per strain, which can be tested for linkage with the affected phenotype. Rapid mutation ﬁnding by BSA
and/or massively parallel sequencing permits the simultaneous investigation of many more phenotypes than was previously possible. In every case, conﬁrmation of
causality depends on knowledge of the effect of a second mutant allele or on transgenic rescue of the mutant phenotype with the wild-type allele.
Moresco et alslide, and ampliﬁed by single-molecule PCR. Ampliﬁcation is
necessary to increase the signal to be detected by the CCD
imaging system but can also introduce sequence and abun-
dance errors that reduce accuracy. The resulting ampliﬁed
fragments are sequenced base by base in a ﬂow cell through
which reagents are cycled and signal is detected. For each
platform, sequencing chemistry is different.67 For example,
complementary reversible dye terminator nucleotides added
by a DNA polymerase are detected by ﬂuorescent emission in
Illumina-Solexa sequencers.68 The ABI/Life Technologies
SOLiD system is based on ligation andﬂuorescent detection of
complementary dinucleotides on the template; multiple cycles
of ligation beginning at consecutive start positions effectively
result in each nucleotide being sequenced twice.69 Pyrose-
quencing, in which light is emitted on addition of comple-
mentary nucleotides by DNA polymerase, is used in Roche/
454 sequencers.70 With the Illumina or Life Technologies
platforms, amouse genome can be sequenced in about 1week.
The abundance and type of data generated by massively
parallel sequencers have necessitated computational re-
sources to both store and process these data efﬁciently. In
particular, whereas sequence data from capillary sequencers
was typically in the form of approximately 500-bp reads,
most massively parallel sequencers produce millions of1466short reads (approximately 50 to 150 bp) at a time. These
must be properly aligned to a reference genome sequence
and then analyzed for mismatches. Because of the inte-
grated, kit-based functionality of the instruments, most
platforms use their own unique software to process raw data
and output sequence information. Because of the short
length of the reads, accurate alignment may be challenging,
especially in areas with repetitive sequences. So-called
mate-pair library construction is a means to address this
issue by incorporating a larger DNA fragment into a circular
DNA, thereby resulting in reads that are separated from one
another by a spacer of relatively constant length. Mate pairs
permit one to jump over repetitive sequences that would
otherwise thwart unambiguous alignments.
Even newer technology for massively parallel sequencing
of individual, linear, unampliﬁed DNA molecules is
currently in development, with several machines already
available. These machines include the HeliScope (Helicos
BioSciences Corp., Cambridge, MA),71 the PacBio RS
(Paciﬁc Biosciences of California, Inc., Menlo Park, CA),72
and the Ion PGM Sequencer (Life Technologies).73 These
instruments use various detection methods to register
nucleotide incorporation by DNA polymerase for millions
of different templates simultaneously.66,67 Single-moleculeajp.amjpathol.org - The American Journal of Pathology
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generation technologies just described. First, the single-
molecule sequencers require less starting DNA material,
thereby eliminating the need for PCR ampliﬁcation and the1 Generate MEFs from 
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The American Journal of Pathology - ajp.amjpathol.orgsequence/abundance errors it introduces. Second, long reads
upward of approximately 2 kb produced by single-molecule
sequencers have the capacity to span regions of repetitive
sequences, facilitating unambiguous alignment to a reference
genome and de novo assembly and alignment of previously
unsequenced genomes. Currently, however, the sequencing
accuracy of single-molecule sequencers is generally far below
that of massively parallel sequencers that depend on PCR
ampliﬁcation. For example, the PacBio RS generated reads
with an average accuracy of 82.1%74 or 84.4%.75 The use of
short, high-accuracy sequences from second-generation PCR-
based sequencers to correct long, single-molecule sequences
has been demonstrated as an effective strategy to improve the
accuracy of sequences from the PacBio RS single-molecule
sequencer.76e78
A New Era of Mutation Finding
The development of massively parallel sequencing has shif-
ted the focus in mutation identiﬁcation from mapping to
sequencing (Figure 2). No longer is mapping to high reso-
lution necessary to narrow a critical region to a few megabase
pairs because the sequence of the whole mouse genome or the
sequence of many different mouse exomes can be determined
with high accuracy using massively parallel sequencing in far
less time (currently about 1 week) than intensive mapping
would require. Quick mapping methods, such as bulk
segregation analysis (BSA), sufﬁce in locating a broad crit-
ical region.79 Like traditional mapping, BSA involves out-
crossing mutants to a mapping strain. F2 offspring are
phenotyped and genotyped for markers across the genome.
However, instead of genotyping individual mice for strain-
speciﬁc markers, allele frequency is determined, based on
sequencing peak trace heights, at each informative locus in
two pools of DNA from F2 mice grouped by phenotype,
either normal or affected. For each marker, enrichment of the
mutant strain allele in the affected DNA pool and depletion in
the normal DNA pool are used to establish linkage.With only
about 20 meioses, BSA can localize a mutation to a sub-
chromosomal region, within which there may be only one
mutation identiﬁed by whole genome sequencing.Figure 3 Somatic cell mutagenesis and recovery of mutations in iPSCs.
Somatic cells, such as ﬁbroblasts, derived from transgenic reprogrammable
mice that inducibly express Oct4, Sox2, Klf4, and c-Myc (1) are mutagenized
and then screened for phenotypes of interest, such as resistance to viral
infection (2). Surviving cells are converted to iPSCs (3) and used to
generate chimeric mice (4a). Resistance to viral infection is tested in
chimeric mice or in mice fully derived from the germline-transmitted iPS
clone (5). iPSCs are also sequenced to identify all induced mutations (4b).
The causative mutation can be identiﬁed by genotyping fully iPSC-derived
mice at all mutation sites and examining segregation patterns for concor-
dance of the phenotype with homozygosity for a particular mutation (6).
For a recessive phenotype, any single gene that sustained compound
heterozygous mutations in the iPSCs is a strong candidate for causation.
Other genes may be prioritized as candidates for causation based on pub-
lished information on function/phenotype.
1467
Moresco et alBecause most ENU-induced phenotype is caused by
changes in coding sequence,43,49 exome sequencing (exonic
DNA capture combined with massively parallel sequencing)
is an alternative to whole genome sequencing that greatly1
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1468reduces the amount of sequencing needed per mouse. Exome
capture involves solution- or microarray-based hybridization
of sheared genomic DNA to either RNA or DNA oligonucle-
otides complementary to nonrepetitive exonic sequences.80e83
Exome sequencing has been used to analyze human DNA for
rare coding variations,84 to identify the basis of several human
genetic diseases,85e88 and to examine tumor genomes.89e91 In
the mouse, exome capture coupled with massively parallel
sequencing has been validated as a robust approach for iden-
tiﬁcation of putative mutations,5,49 including those with low
phenotypic penetrance.92 Several commercial kits for exome
capture have recently become available for the mouse, with
capture efﬁciency (frequency of DNA being exonic) ranging
from 40% to 55% for the Nimblegen (Roche NimbleGen, Inc.,
Madison, WI) and Agilent (Agilent Technologies, Inc., Santa
Clara, CA) kits.5 A beneﬁt of both genome and exome
sequencing is the capture of many incidental mutations, which
are not responsible for the phenotype in question but may be
useful tools for the investigation of other phenotypes.
The possibility of mutation identiﬁcation directly from
massively parallel exome sequencing data has recently been
demonstrated.5 A total of 12 ENU-mutagenized strains with
either immune disorders or obesity were analyzed. Whole-
exome capture was performed using solution-based hybrid-
ization to either biotinylated RNA or DNA oligonucleotides,
followed by ampliﬁcation and sequencing of the exome-
enriched DNA. Despite an expected number of approxi-
mately 50 mutations per animal based on estimates of ENU
mutation frequency, approximately 10,000 single nucleotide
changes were identiﬁed in raw data for each mouse
sequenced. The key to successful identiﬁcation of the caus-
ative mutations was the application of several ﬁlters to the list
of variants. These ﬁlters excluded intronic variants, synon-
ymous nucleotide changes, and variants listed in the Single-
Nucleotide Polymorphism database (http://www.ncbi.nlm.
nih.gov/projects/SNP). Another important ﬁlter excluded
variants that recurred in more than one unrelated mouse from
the colony; this ﬁlter effectively removed systematic false-
positive variants that resulted from the exome enrichment
and sequencing processes. Finally, with the reasoning that
ENU is unlikely to induce more than one mutation in any
gene in a single mouse, a ﬁlter for genes with multiple variant
calls further reduced the putative mutation list. With one
exception, the combination of ﬁlters reduced the number of
homozygous variants to <10 per mouse and 6 on average.Figure 4 Use of mouse haploid ESCs for forward genetics. The ﬁrst four
steps are for the derivation of haploid ESCs, which can be mutagenized (5),
such as with ENU or gene trap vectors. Single cell clones of mutagenized
haploid ESCs can be expanded (6) and then screened for phenotypes of
interest (7a). They may also be differentiated into specialized cell types,
such as macrophages (7b), or injected into recipient blastocysts to
generate chimeric mice (7c); both of these processes result in diploidiza-
tion of the haploid ESCs. The resulting differentiated cells and chimeric
mice thus carry the induced mutations in homozygous state, permitting
screening for recessive phenotypes (8b and 8c). Mutations may be iden-
tiﬁed by mapping and/or sequencing as appropriate.
ajp.amjpathol.org - The American Journal of Pathology
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original pedigrees deﬁnitively established the causative
mutation without further need for meiotic mapping. A similar
ﬁltering strategy was successfully applied to custom exome
sequence data to identify ENU-induced mutations in four
mutant lines, with only minimal mapping performed during
stock maintenance.93
Although minimal mapping saves time at the front end of
a project, it can result in a greater burden later on if it becomes
necessary to prove causality. Unexpected genetic ﬁndings
may require veriﬁcation by quite reﬁned mapping of a critical
region, especially if other candidate genes lie close by. This
issue may be addressed by sequencing candidate genes
directly to demonstrate the absence of mutations in animals
with the mutant phenotype. Generating transgenic mice
carrying the mutant allele might also be performed, if the
mutation is dominant, to recapitulate the mutant phenotype,
or in the case of a recessive mutation, transgenic rescue of the
mutant phenotype with the wild type allele can be performed
in support of causality. Phenotypic analysis of a knockout
mouse, which may already exist in a repository such as the
Knockout Mouse Project Repository (https://www.komp.org,
last accessed March 11, 2013), might be easily performed to
demonstrate a recapitulation of the mutant phenotype.
We note that mutation ﬁnding for complex phenotypes
will also beneﬁt from massively parallel sequencing tech-
nology. The mapping of complex phenotypes, typically
among divergent mouse strains, follows the same principles
as the mapping of monogenic traits, although the more loci
involved, the more difﬁcult it is to map and identify all
causative loci. With massively parallel sequencing, it will be
possible to have in hand the complete list of nucleotide
changes within a group of animals expressing a complex
phenotype. Together with coarse mapping, such as by BSA,
and evaluation of the potential degree of damage from amino
acid substitutions by prediction tools such as PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2),94 the list of candi-
date genes might be substantially narrowed before biological
proof of causality is sought, for example, through trans-
genesis or creation of a knockin mutation.Estimating Genome Saturation
In conducting a forward genetic screen, it is useful to know
what fraction of the genome has been mutated to a state of
detectable phenovariance. If this can be done, one may use the
number of hits obtained in the screen to estimate the total
number of genes with an essential function in the phenomenon
of interest.Knowing the types ofmutations causedbyENUand
the frequency with which they each occur,43,44 one may
simulate mutagenesis in silico, modeling the introduction of
mutations into spermand tracking their transmission toG1,G2,
and G3 mice in keeping with pedigrees actually produced and
screened. In this way, a plausible estimate of genetic damage
surveyed among a given population of G3 mice can be made.The American Journal of Pathology - ajp.amjpathol.orgWithin such a population, which has actually been
screened for phenotype, one may determine the number of
simulated homozygous overt null alleles (mutations pre-
dicted with high conﬁdence to inactivate proteins by causing
premature truncation of translation products or splicing
defects). On the basis of empirical determination of the
frequency with which missense mutations cause phenotyp-
ically detectable effects,43 one may also estimate the number
of simulated homozygous missense mutations that are likely
to cause functional inactivation of gene products among the
G3 mice screened. With knowledge of the number of
recessive phenovariants actually detected in the population
and knowledge of the fraction of genes that have been
functionally inactivated, one may estimate the total number
of genes that make an essential and nonredundant contri-
bution to the biological phenomenon of interest.
The need for simulation will undoubtedly diminish as
sequencing costs decline, permitting more direct assess-
ments of the amount of genetic damage present in a given
population of G3 mice. However, at present, it continues to
offer a useful estimate of the size of the target gene
population.The Future of Forward Genetics
As mutation identiﬁcation becomes more efﬁcient and less
expensive as a result of new sequencing technology, the
creation and analysis of phenotype may replace mutation
ﬁnding as the bottlenecks in forward genetics. Future efforts
will therefore likely focus on the rapid generation of
phenotypes and their systematic analysis. One approach
may be to use cell-based phenotypic screening to increase
the rate at which mutant phenotypes are identiﬁed. An
interesting possibility would be to mutagenize somatic cells
(for example, ﬁbroblasts), provided the phenotype of
interest (for example, resistance to infection by a particular
virus) can be detected in such cells (Figure 3). Surviving
ﬁbroblasts could then be expanded and converted to
iPSCs,12 which are similar to ESCs in pluripotency.95
Conversion to iPSCs may be facilitated by derivation of
the ﬁbroblasts from a transgenic, reprogrammable mouse
engineered to express the reprogramming genes Oct4, Sox2,
Klf4, and c-Myc under a tetracycline-inducible promoter;
ﬁbroblasts could be converted to iPSCs by exposure to
tetracycline. The iPSCs, bearing a heavy burden of muta-
tions, could be injected into blastocysts to produce chimeric
mice, with eventual germline transmission of mutations
induced by ENU.96 At the same time, DNA from the iPS
clone could be sequenced to detect all mutations that were
induced. Although dominant phenotypes resulting from
heterozygous mutations might be detected in screening,
particular attention might be accorded compound hetero-
zygous mutations at single loci, which might be indicative
of recessive phenotypes. Either at the chimeric stage or later,
in progeny derived from mutation-bearing germ cells,1469
Moresco et alconﬁrmation of phenovariance could be sought by exam-
ining resistance to viral infection. Positional cloning of the
causative mutation or exome sequencing and segregation
analysis could be undertaken provided germline trans-
mission of mutations could be achieved.
With such a method, millions of cells might be muta-
genized and screened simultaneously in vitro, as opposed to
screening a few hundred mutagenized mice at a time. Only
those with interesting phenotypes would be reconstituted as
live animals for further study of the mutation in a physio-
logical setting. Equally important is the utility of this
strategy in circumventing difﬁculties encountered in
creating homozygous mutations in mice, now normally
achieved by breeding G1 mice to produce G2 animals and
ﬁnally G3 animals homozygous for ENU-induced muta-
tions. Among the limitations of germline mutagenesis,
mutations that affect a given biological process (eg, TLR
signal transduction) will not be detected if they also cause
lethality related to developmental anomalies. If it is possible
to screen mutagenized somatic cells or chimeric mice
derived from iPSCs, genes with a dual role in development
and immunity might be far easier to identify.
Haploid ESCs also promise to accelerate the creation and
analysis of phenotype in mouse forward genetic studies.
Derived from parthenogenetic induction of oocyte division,
haploid ESCs are harvested from the inner cell mass of
blastocysts and can be mutagenized and then grown clon-
ally.13,14 With the caveat that haploid ESCs frequently
convert to the diploid state (for one clonal population, at
a frequency of 2% to 3% each day14) and so must be
habitually sorted to maintain a pure haploid population, they
can be differentiated into multiple diploid cell types carrying
induced mutations in homozygous state. Alternatively,
when injected into fresh blastocysts, haploid ESCs gain
a diploid karyotype, giving rise to chimeric mice with cells
homozygous for induced mutations. Ultimately, such
mutations can be transmitted in the germline.97 Because
there is no need for extensive breeding or involved proce-
dures to generate homozygous mutant animals or cells,
haploid ESCs should enable high-throughput gene inacti-
vation that leads rapidly to phenotypic analysis of recessive
traits (Figure 4). Moreover, mutagenesis of haploid ESCs
may be applied to many different genetic backgrounds;
there is no need to generate a lengthy and expensive pipeline
of mutants spanning three generations. Screens for the
suppression of phenotypes induced by other mutations may
be feasible, for example, screens for suppression of complex
disease phenotypes. Screening haploid ESCs or chimeras
derived from them also bypasses lethality that may be
caused by developmental defects in whole animals.Conclusion
The process of mutation ﬁnding has been markedly acceler-
ated recently, and the use of mutagenesis to provide quick1470insight into biological puzzles has been facilitated accordingly,
so much that creation and systematic analysis of phenotype
may become rate-limiting in mouse forward genetic studies.
The development of reliable and streamlined protocols for
high-throughput mutagenesis, screening, and generation of
homozygous mice from IPSCs and haploid ESCs may help
address a phenotypic shortage and permit multiple pipelines of
mutagenesis where at present even a single pipeline is
expensive to maintain. Forward genetic screens for mutations
that cause suppression of disease phenotypes may help in
deciphering the mechanism by which certain mutations
produce phenotypes. Mutated genes identiﬁed as suppressors
might be pursued as drug targets, even if the mechanism of
disease suppression is not yet understood.
More critical, however, for the forward genetic approach
is that mechanistic insight often lags far behind the
discovery of new phenotypes and their mutational causes.
Genetics creates an embarrassment of riches: embarrassing
because we often see dramatic phenotypes and understand
their primary causes but do not understand their secondary
or tertiary causes well at all. Structural biology, cell biology,
and biochemistry often provide insight into mechanism
where genetics cannot and may be the most appropriate
tools for exploiting genetic gains.
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